venBio Partners LLC

Q3 2026 13F-HR Holdings

Location
San Francisco, CA
Holdings as of
9/30/2026
Date filed
11/16/2026
Form type
13F-HR
Num holdings
9
Total value ($000)
$495,928
Net value change ($000)
-23,452 (-4.5%)
New positions
3
Sold out positions
1
Turnover %
20.5%
Sector allocation + QoQ delta (equities-only)

Snapshot: Change Analysis

Compared to Q2 2026
Methodology: sector metrics are equities-only; instrument mix chart is ex-options; options exposure is shown separately. Why this matters.
Top Adds (Value $000, Stocks/ETFs)
ATTOVIA THERAPEUTICS INC 71,669 NEW
PARABILIS MEDICINES INC 25,913 18.0%
YARROW BIOSCIENCE INC 12,493 NEW
ACHV 9,227 23.9%
LSTA 225 NEW
Top Reduces (Value $000, Stocks/ETFs)
ALMS -96,454 -75.7%
PHVS -19,131 -11.9%
HRMY -17,193 -100.0%
ALXO -8,761 -32.8%
LYEL -1,439 -30.3%
Instrument mix + QoQ Δ (ex-options)
How this table is calculated: SEC VALUE ($000) is used as reported. For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received. Column % is bucket-based: non-options share is calculated inside non-option total, options share is calculated inside options total. Details.
Filter:
Instrument:
Issuer Name Ticker Sector Industry Class History Value ($000) % Shares Shares Δ Shares Δ% Value Δ ($000) Value Δ% Principal Option Type